Case Report
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 26, 2024; 12(21): 4813-4819
Published online Jul 26, 2024. doi: 10.12998/wjcc.v12.i21.4813
Hepatoid adenocarcinoma of the lung: A case report
Yi-Jun Mo, Li-Na Lin, Jing-Li Tao, Tao Zhang, Jian-Hua Zhang
Yi-Jun Mo, Tao Zhang, Jian-Hua Zhang, Department of Thoracic Surgery, Shenzhen Hospital, Southern Medical University, Shenzhen 518104, Guangdong Province, China
Li-Na Lin, School of Nursing, Guangzhou Xinhua University, Guangzhou 510520, Guangdong Province, China
Jing-Li Tao, Department of Pathology, Shenzhen Hospital, Southern Medical University, Shenzhen 518104, Guangdong Province, China
Co-first authors: Yi-Jun Mo and Li-Na Lin.
Author contributions: Mo YJ and Lin LN contributed to the conception and design of the study; All authors participated in the clinical practice, including diagnosis, treatment, consultation and follow up of patients; Tao JL and Zhang T contributed to the acquisition of data; Zhang JH and Mo YJ contributed to the analysis of data; Lin LN wrote the manuscript; Mo YJ and Tao JL revised the manuscript; All authors approved the final version of the manuscript.
Supported by Research Fund of Basic Research Project of Shenzhen (Natural Science Foundation of Shenzhen), No. JCYJ20230807142205010.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors declare that they have no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https: //creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Na Lin, MD, Research Fellow, School of Nursing, Guangzhou Xinhua University, No. 19 Huamei Road, Guangzhou 510520, Guangdong Province, China. linlinadr@163.com
Received: April 13, 2024
Revised: May 22, 2024
Accepted: June 13, 2024
Published online: July 26, 2024
Processing time: 78 Days and 4.2 Hours
Abstract
BACKGROUND

Hepatoid adenocarcinoma of the lung (HAL) is a rare type of non-small cell lung cancer (NSCLC), histologically similar to hepatocellular carcinoma. HAL has high malignancy and poor prognosis, and a better treatment plan needs further study.

CASE SUMMARY

In order to deeply understand the occurrence and development of HAL, here we report a case of HAL with extensive metastasis of alpha fetoprotein negative KRAS A146T mutation. The patient refused chemotherapy and received one course of treatment (immune checkpoint inhibitors), and died three months later due to progressive disease.

CONCLUSION

HAL is a special type of NSCLC. The surgical treatment of HAL in the limited stage can achieve long-term survival, but most of them were in the advanced stage when they were found, and the prognosis was poor, which requires multidisciplinary comprehensive treatment.

Keywords: Hepatoid adenocarcinoma, Histopathological characteristics, Non-small cell lung cancer, Hepatoid adenocarcinoma of the lung, Case report

Core Tip: Hepatoid adenocarcinoma of the lung is a special type of non-small cell lung cancer, which is mainly seen in men who smoke heavily. It usually occurs in the upper lobes of both lungs, showing huge masses.